Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H18Cl2N8.2ClH |
| Molecular Weight | 538.26 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CC1=CNC(=N1)C2=CN=C(NCCNC3=NC=C(C=C3)C#N)N=C2C4=CC=C(Cl)C=C4Cl
InChI
InChIKey=OOMHEMQQCHEWDS-UHFFFAOYSA-N
InChI=1S/C22H18Cl2N8.2ClH/c1-13-10-29-21(31-13)17-12-30-22(32-20(17)16-4-3-15(23)8-18(16)24)27-7-6-26-19-5-2-14(9-25)11-28-19;;/h2-5,8,10-12H,6-7H2,1H3,(H,26,28)(H,29,31)(H,27,30,32);2*1H
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12606497
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12606497
CHIR 99021 is a selective, pyridimidine-based, glycogen synthase kinase 3 inhibitor that is effective at low nanomolar concentrations in enzyme assays and submicromolar concentrations in isolated cells and tissues. Chiron was developing CHIR 99021 for potential use in the treatment of type 2 diabetes mellitus. CHIR 99021 promoted insulin-mediated glucose uptake and increased glucose disposal in rodent models of diabetes. However, there has been no recent development reported.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. | 1993 Aug 15 |
|
| Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. | 1999 Aug |
|
| Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. | 2000 Feb |
|
| Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. | 2003 Mar |
|
| Coordinated waves of gene expression during neuronal differentiation of embryonic stem cells as basis for novel approaches to developmental neurotoxicity testing. | 2011 Mar |
|
| Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy. | 2011 Nov |
|
| Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. | 2012 May 23 |
|
| Roles of glycogen synthase kinase 3 in Alzheimer's disease. | 2012 Sep |
|
| Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation. | 2015 May 29 |
|
| Analysis of Glycogen Synthase Kinase Inhibitors That Regulate Cytochrome P450 Expression in Primary Human Hepatocytes by Activation of β-Catenin, Aryl Hydrocarbon Receptor and Pregnane X Receptor Signaling. | 2015 Nov |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
X6BE5J2G31
Created by
admin on Sat Dec 16 16:33:08 GMT 2023 , Edited by admin on Sat Dec 16 16:33:08 GMT 2023
|
PRIMARY | |||
|
91826519
Created by
admin on Sat Dec 16 16:33:08 GMT 2023 , Edited by admin on Sat Dec 16 16:33:08 GMT 2023
|
PRIMARY | |||
|
2109414-84-6
Created by
admin on Sat Dec 16 16:33:08 GMT 2023 , Edited by admin on Sat Dec 16 16:33:08 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
